Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 45 · MACD below its signal
None of the 29 investors followed here reported a position in SGIOY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Alan Armstrong Sen. OK | 1 | +$8.0K | Bought Mar 30, 26 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Mar 30, 26 | Alan Armstrong Sen. OK | Self | Buy | $1,001 - $15,000 | Jul 21, 26 (113d) | Report |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SGIOY.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.8 | 14.0 | -4.8 | -9.2 | -7.2 | -8.6 | 5.9 | 0.0 | 0.2 | -2.6 | −1.8% | ||
| 2025 | 9.8 | -2.7 | 0.9 | 11.1 | -1.0 | 8.0 | -6.5 | 3.4 | 1.6 | -5.6 | 3.9 | 4.6 | +29.0% |
| 2024 | 0.1 | 3.5 | 2.7 | -9.4 | -2.9 | -13.4 | 12.3 | 6.5 | -7.1 | -1.2 | -1.5 | -0.6 | −12.8% |
| 2023 | -4.3 | -7.0 | 2.1 | -0.6 | -0.5 | -5.8 | 1.9 | 2.5 | 1.5 | 4.8 | 0.7 | 2.1 | −3.3% |
| 2022 | -16.6 | 13.2 | -7.9 | -9.9 | -4.0 | -4.8 | 0.9 | -4.9 | -0.7 | -3.7 | 9.5 | -2.4 | −29.9% |
| 2021 | -0.9 | -5.2 | 5.0 | -2.4 | -3.2 | 1.8 | 1.4 | 19.7 | 8.4 | -4.8 | 6.7 | 1.5 | +28.9% |
| 2020 | -3.9 | -11.0 | -8.5 | 12.4 | 6.4 | 8.0 | -6.0 | -6.1 | -3.0 | -12.7 | 13.5 | 2.9 | −11.9% |
| 2019 | 8.2 | 5.9 | -4.8 | -5.1 | -6.8 | 4.7 | -2.7 | -4.1 | 2.0 | 10.5 | -1.3 | 5.1 | +10.1% |
| 2018 | 4.8 | -9.3 | -1.0 | -0.1 | -0.5 | 0.6 | 5.5 | 8.7 | 6.1 | 0.5 | 4.3 | -14.8 | +2.2% |
| 2017 | 2.6 | 5.2 | -0.4 | 8.4 | -1.7 | 7.6 | -6.7 | -1.1 | -0.7 | 7.5 | 0.0 | -1.3 | +19.9% |
| 2016 | -3.6 | 0.5 | 3.4 | 10.2 | 11.5 | 4.3 | -4.2 | -14.2 | -4.7 | 9.8 | -3.9 | -4.9 | +0.9% |
| 2015 | — |
Buy / hold / sell counts
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.